Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206966 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10GLA | |
| SCHEMBL3815180 | 0.89 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAMAPTLMNA | |
| SCHEMBL4214562 | 0.89 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAMAPTLMNA | |
| SCHEMBL3860431 | 0.89 | ALDH1A1 (0.53) | ALDH1A1HSD17B10GAAMAPTLMNA | |
| SCHEMBL3205373 | 0.84 | TSHR (0.49) | ALDH1A1KDM4EGLATSHRMAPT | |
| SCHEMBL5205180 | 0.84 | TSHR (0.49) | ALDH1A1KDM4EGLATSHRMAPT | |
| SCHEMBL3806023 | 0.84 | TSHR (0.49) | ALDH1A1KDM4EGLATSHRMAPT | |
| SCHEMBL3805744 | 0.84 | EPHX1 (0.47) | ALDH1A1HSD17B10GLATSHRMAPT | |
| SCHEMBL3222025 | 0.82 | TSHR (0.46) | ALDH1A1KDM4EHSD17B10GLAGAA | |
| SCHEMBL1951762 | 0.82 | TSHR (0.46) | ALDH1A1KDM4EHSD17B10GLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | HOSSAIN NAFIZAL | 2009-12-03 | — | — | US | disclosed |
| US-7524856-B2 | Tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-7449475-B2 | Tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2008-11-11 | — | — | US | disclosed |
| EP-1521757-B1 | TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070203230-A1 | Novel Tricyclic Spiroderivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB | 2007-08-30 | — | — | US | disclosed |
| US-20070203229-A1 | Novel Tricyclic Spiroderivatives as Modulators of Chemokine Receptor Activity | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ASTRAZENECA AB (SE) | 2007-05-03 | — | — | US | disclosed |
| US-20070021498-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | US | disclosed |
| EP-1699791-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| EP-1678156-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2006-07-12 | — | — | EP | disclosed |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005061499-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037814-A1 | NOVEL TRICYCLIC SPIRODERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | WO | disclosed |
| EP-1521757-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004005295-A1 | NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062322-A1 | Novel Tricyclic Spiropiperidines or Spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1465/4885KDM4E 2276/4885HPGD 2996/4885 |
| US-20070099945-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor acitivity | ACKR3, CXCR1, CXCR2 | ALDH1A1 707/4885KDM4E 4545/4885HPGD 492/4885 |
| US-20070203230-A1 | Novel Tricyclic Spiroderivatives as Modulators of Chemokine Receptor Activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 1603/4885KDM4E 4136/4885HPGD 1439/4885 |
| US-20070203229-A1 | Novel Tricyclic Spiroderivatives as Modulators of Chemokine Receptor Activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 1603/4885KDM4E 4136/4885HPGD 1439/4885 |
| US-20110124613-A1 | Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma | GRK5, ADRB2, GRK2 | ALDH1A1 1412/4885KDM4E 2432/4885HPGD 904/4885 |
| US-20050245741-A1 | Novel tricyclic spiropiperidines or spiropyrrolidines | REN, TACR1, AGTR1 | ALDH1A1 1375/4885KDM4E 2324/4885HPGD 2978/4885 |
| US-20090298861-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 946/4885KDM4E 4477/4885HPGD 680/4885 |
| US-20070021498-A1 | Novel tricyclic spiroderivatives as modulators of chemokine receptor activity | CXCR1, CXCR2, CXCR4 | ALDH1A1 1292/4885KDM4E 4056/4885HPGD 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.